Tyra Biosciences, Inc. Stockholders Equity

Quick Answer

Tyra Biosciences, Inc. reported Stockholders Equity of $259.18 million for fiscal year 2025.

Tyra Biosciences, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $259.18M -24.5%
2024 $343.15M +68.0%
2023 $204.26M -20.8%
2022 $257.83M -14.6%
2021 $301.74M +2312.5%
2020 -$13.64M -187.7%
2019 -$4.74M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $280.51M -22.6% -7.2%
June 30, 2025 $302.15M -19.7% -6.6%
March 31, 2025 $323.53M -17.0% -5.7%
December 31, 2024 $343.15M +68.0% -5.3%
September 30, 2024 $362.29M +63.1% -3.7%
June 30, 2024 $376.04M +57.6% -3.5%
March 31, 2024 $389.88M +56.7% +90.9%
December 31, 2023 $204.26M -20.8% -8.1%
  • Tyra Biosciences, Inc. showed a decrease of -24.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2019–2025 period, Tyra Biosciences, Inc.’s stockholders equity has grown by 5566.7% (from -$4.74 million to $259.18 million).
  • The most recent figure is from Tyra Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment